2020 Q2 Financial Review

Unimicron


Jul. 29, 2020

Disclaimer

- Except for statements in respect of historical matters, the statements in this release are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual performance, financial condition or results of operations of Unimicron to be materially different from what may be implied by such forward-looking statements.
- The financial forecasts and forward-looking statements in this release reflect the current belief of Unimicron as of the date of this release and Unimicron undertakes no obligation to update these forecasts and forward-looking statements for events or circumstances that occur subsequent to such date.
- The statements in respect of historical matters may contain unaudited information, which may have certain deficiency or weakness so as not to fairly present financial condition or the result of operations of Unimicron.

Unimicron

Consolidated Sales & Gross Margin Trend



Unimicron

Consolidated Statements of Comprehensive Income – QoQ

	00.00	0/	04.00	0/	NTD:M
	Q2-20	%	Q1-20	%	QoQ %
Net Sales	21,710	100.0	20,567	100.0	6
Cost of sales	(18,290)	(84.2)	(17,708)	(86.1)	3
Gross Profit	3,420	15.8	2,859	13.9	20
Operating Expenses	(2,084)	(9.6)	(2,024)	(9.9)	3
Other Income and Expenses	(15)	(0.1)	18	0.1	(183)
Operating Income	1,321	6.1	853	4.1	55
Net Non-operating Income and Expenses	474	2.2	(338)	(1.6)	240
Income before tax	1,795	8.3	515	2.5	249
Income Tax Expense	(313)	(1.5)	(278)	(1.3)	13
Net Income	1,482	6.8	237	1.2	525
Other Comprehensive Income and Losses	(152)	(0.7)	(284)	(1.4)	<i>4</i> 6
Comprehensive Income (Loss)	1,330	6.1	(47)	(0.2)	2930
Net Income (Loss) Attributable to:					
Shareholders of the Parent	1,435	6.6	382	1.9	
Non-controlling Interests	47	0.2	(145)	(0.7)	
Net Income	1,482	6.8	237	1.2	
EBITDA	4,089		2,822		
%(Sales)	19%		14%		
EPS (Basic)	0.99		0.26		
(Diluted)	0.98		0.26		

CONFIDENTIAL

Unimicron

Consolidated Statements of Comprehensive Income – YoY

					NTD:M
	H1-20	%	H1-19	%	Yo Y %
Net Sales	42,277	100.0	37,014	100.0	14
Cost of sales	(35,998)	(85.1)	(32,458)	(87.7)	11
Gross Profit	6,279	14.9	4,556	12.3	38
Operating Expenses	(4,108)	(9.8)	(3,623)	(9.8)	13
Other Income and Expenses	3	0.0	(6)	0.0	150
Operating Income	2,174	5.1	927	2.5	135
Net Non-operating Income ar	136	0.4	300	0.8	(55)
Income before tax	2,310	5.5	1,227	3.3	88
Income Tax Expense	(591)	(1.4)	(372)	(1.0)	59
Net Income	1,719	4.1	855	2.3	101
Other Comprehensive Incom	(436)	(1.0)	116	0.3	(477)
Comprehensive Income	1,283	3.0	971	2.6	32
Net Income (Loss) Attributable to):				
Shareholders of the Parent	1,817	4.3	919	2.5	
Non-controlling Interests	(98)	(0.2)	(64)	(0.2)	
Net Income	1,719	4.1	855	2.3	
EBITDA	6,912		5,823		
%(Sales)	16%		16%		
EPS (Basic)	1.25		0.63		
(Diluted)	1.24		0.62		

CONFIDENTIAL

Unimicron

Consolidated Balance Sheets

	2020		2020		2020	NTD:M
	JUN.30	%	MAR.31	%	DEC.31	%
Cash	23,339	20.5	22,522	20.2	20,586	18.7
Accounts Receivable	17,475	15.3	17,108	15.3	17,983	16.3
Inventories	9,355	8.2	8,951	8.0	8,718	7.9
Other Current Assets	2,371	2.1	2,170	1.9	2,675	2.4
Long-term Investments	5,270	4.6	4,964	4.5	5,611	5.1
Fixed Assets & Investment Property	52,216	45.9	51,851	46.5	50,386	45.7
Total Assets	113,859	100.0	111,549	100.0	110,202	100.0
Short-term Loans	10,846	9.5	11,526	10.3	11,150	10.1
Long-term Liabilities-Current	7,109	6.2	5,057	4.5	3,011	2.7
Other Current Liabilities	22,941	20.1	21,184	19.0	22,045	20.0
Long-term Liabilities	19,494	17.1	20,690	18.5	21,653	19.6
Shareholders' Equity	48,475	42.6	48,629	43.6	48,351	43.9
Net Inventory						
Turnover Days	46		46		43	
Net Accounts Receivable						
Turnover Days	75		76		75	



c⁹NFIDENTIAL</sup>

Consolidated Statements Of Cash Flows – QoQ

		NTD:M
	Q2-20	Q1-20
Income before tax	1,795	515
Depreciation and Amortization	2,181	2,163
Others	(852)	735
Net Cash Provided by Operating Activities	3,124	3,413
Acquisition of Fix Assets & Investment Property	(3,065)	(3,138)
Decrease in Investments	8	591
Others	132	242
Net Cash Used by Investing Activities	(2,925)	(2,305)
Increase in Loans	573	995
Others	40	(21)
Net Cash Provided by Financing Activities	613	974
Effect of Exchange Rates Changes	5	(146)
Increase in Cash	817	1,936
Cash at End of Period	23,339	22,522


Unimicron

Consolidated Statements Of Cash Flows – YoY

	H1-20	NTD:M H1-19
Income before tax	2,310	1,227
Depreciation and Amortization	4,344	4,277
Others	(118)	(530)
Net Cash Provided by Operating Activities	6,536	4,974
Acquisition of Fix Assets & Investment Property	(6,203)	(5,844)
Decrease in Investments	598	(464)
Others	375	168
Net Cash Used by Investing Activities	(5,230)	(6,140)
Increase (Decrease) in Loans	1,568	467
Others	19	37
Net Cash Provided (Used) by Financing Activities	1,587	504
Effect of Exchange Rates Changes	(140)	(54)
Increase (Decrease) in Cash	2,753	(716)
Cash at End of Period	23,339	22,097


Unimicron

Sales Breakdown by Technology - QoQ




Unimicron

Sales Breakdown by Application - QoQ




Sales Breakdown by Technology - YoY



Unimicron

Sales Breakdown by Application - YoY



Unimicron

謝謝您的聆聽

Unimicron

Thank you